Last reviewed · How we verify
SEL-037
At a glance
| Generic name | SEL-037 |
|---|---|
| Also known as | Pegadricase |
| Sponsor | Selecta Biosciences, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy II (PHASE3)
- A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy (PHASE3)
- Multi-Dose Safety/Pharmacodynamic Study of SEL-212/SEL-037 in Subjects With Symptomatic Gout & Elevated Blood Uric Acid (PHASE2)
- Safety and Pharmacodynamics of SEL-212 (Pegsiticase + SEL-110) in Subjects With Elevated Blood Uric Acid Levels (PHASE1)
- Safety and Pharmacodynamics of SEL-037 (Pegsiticase) in Subjects With Elevated Blood Uric Acid Levels (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SEL-037 CI brief — competitive landscape report
- SEL-037 updates RSS · CI watch RSS
- Selecta Biosciences, Inc. portfolio CI